CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A mathematical model of CAR-T cell therapy in combination with chemotherapy for malignant gliomas.
A mathematical model of CAR-T cell therapy in combination with chemotherapy for malignant gliomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
恶性胶质瘤(MG)是侵袭性最强的原发性脑肿瘤之一,具有高度治疗耐药性和不良预后。本研究建立数学模型,探究化疗与嵌合抗原受体细胞疗法联合作用下MG的动态变化。所提出的模型为五维动力系统,并纳入代表临床化疗及免疫治疗给药的脉冲输入。我们证明,在非负初始条件下,解保持非负,确保模型具有生物学合理性。结果显示,若两种疗法均仅实施一次,系统轨迹将被吸引至对应肿瘤承载能力的不变曲面。相反,持续给予两种治疗时,在一定参数范围内可实现肿瘤清除。此外,我们通过数值方法研究多种治疗组合,以确定群体层面的最佳方案。为此,我们生成了104名虚拟患者组成的队列,从具有临床意义的范围内均匀抽取模型参数,并开展计算机模拟临床试验。结果表明,肿瘤生长速率、化疗疗效及肿瘤诱导的免疫抑制是决定生存结局的关键因素。我们认为,这些结果为优化治疗提供了新的理论见解,并为改进MG疗法临床试验设计提供了框架。
Malignant gliomas (MGs) are among the most aggressive primary brain tumors, characterized by a high degree of resistance to therapy and poor prognosis. In this work, we develop a mathematical model to investigate the dynamics of MG under the combined effects of chemotherapy and chimeric antigen receptor cell therapy. The proposed model is a five-dimensional dynamical system incorporating impulsive inputs that correspond to the clinical administration of chemotherapy and immunotherapy.
We demonstrate the non-negativity of solutions for non-negative initial conditions, ensuring the biological relevance of the model.
We show that if we apply both therapies only once, the trajectories are attracted to an invariant surface corresponding to the tumor carrying capacity. Conversely, under constant administration of both treatments, we identify parameter ranges in which tumor eradication is achievable.
Furthermore, we numerically study various treatment combinations to determine optimal protocols at the population level. To this end, we generate a cohort of 104 virtual patients with model parameters sampled uniformly within clinically relevant ranges and carry out in silico trials.
Our findings indicate that tumor growth rate, chemotherapy efficacy, and tumor-induced immunosuppression are the key determinants of survival outcomes.
We believe that our results provide new theoretical insights into treatment optimization and offer a framework for refining the design of clinical trials for MG therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。